v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 27 Months Ended 33 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 28, 2026
Aug. 04, 2026
Restructuring Cost and Reserve [Line Items]              
Restructuring charges [1] $ 419.0 $ (74.0) $ 468.0 $ 547.0      
Productivity and Operational Efficiencies [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring charges     17.0        
Biopharma [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring charges 390.0 (406.0) 421.0 211.0      
Realigning Our Cost Base Program [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring cost incurred to date 4,900.0   4,900.0   $ 4,900.0 $ 4,900.0  
Realigning Our Cost Base Program [Member] | Subsequent Event [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost             $ 7,300.0
Realigning Our Cost Base Program [Member] | Biopharma [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring cost incurred to date 3,800.0   3,800.0   3,800.0 3,800.0  
Restructuring charges 417.0 (25.0) 464.0 562.0   3,300.0  
Realigning Our Cost Base Program [Member] | Biopharma [Member] | Subsequent Event [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost             4,800.0
Realigning Our Cost Base Program - Initial Phase [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost 4,700.0   4,700.0   4,700.0 4,700.0  
Realigning Our Cost Base Program - Initial Phase [Member] | Biopharma [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost 3,400.0   3,400.0   3,400.0 3,400.0  
Realigning Our Cost Base Program - Productivity Enhancements | Subsequent Event [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost             2,000.0
Realigning Our Cost Base Program - Productivity Enhancements | Biopharma [Member] | Subsequent Event [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost             800.0
Realigning Our Cost Base Program - Research and Development [Member] | Biopharma [Member] | Productivity and Operational Efficiencies [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost 600.0   600.0   600.0 600.0  
Manufacturing Optimization Program [Member] | Biopharma [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring cost incurred to date 1,100.0   1,100.0   1,100.0 1,100.0  
Restructuring charges (29.0) $ (408.0) (52.0) $ (412.0) 824.0    
Manufacturing Optimization Program [Member] | Biopharma [Member] | Subsequent Event [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost             5,400.0
Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost $ 1,400.0   $ 1,400.0   $ 1,400.0 $ 1,400.0  
Manufacturing Optimization Program - Phase Two [Member] | Biopharma [Member] | Subsequent Event [Member]              
Restructuring Cost and Reserve [Line Items]              
Expected restructuring cost             $ 4,000.0
Non-cash expenditures, percentage of expected cost             60.00%
Cash expenditures, percentage of expected cost             40.00%
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $390 million for the three months ended June 28, 2026 (including charges of $417 million for our Realigning our Cost Base Program and credits of $29 million for our Manufacturing Optimization Program), (ii) charges of $421 million for the six months ended June 28, 2026 (including charges of $464 million for our Realigning our Cost Base Program and credits of $52 million for our Manufacturing Optimization Program), (iii) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program) and (iv) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program). For 2025, Employee terminations included revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.